TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03457532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gumarontinib Tablets
Description: 25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
Study: NCT01767441

Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Description: Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His

Intervention type: OTHER
Intervention: diet treatment
Description: Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
Study: NCT00263705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine
Description: Capecitabine 2000 mg/m² daily six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine in aduvant setting
Description: capecitabine in aduvant setting in ederly with breast cancer
Study: NCT01775059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated sensor and infusion set.
Study: NCT01605552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues (BtB)
Description: BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
Study: NCT01073605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotonorm
Description: 0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
Study: NCT01838499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI8968
Description: SC injection at baseline, Week 4 and Week 8

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: SC injection at baseline, Week 4 and Week 8
Study: NCT03336684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Rheumatoid arthritis patients will be provided with disease education literature
Study: NCT02246387

Intervention type: PROCEDURE
Intervention: Manchester Operation
Description: A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
Study: NCT04286893

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow mediated vasodilatation
Description: Measurement of brachial artery diameter change before and after limb ischaemia.

Intervention type: DIAGNOSTIC_TEST
Intervention: High resolution ECG
Description: Measurement HRV using high resolution ECG

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood withdrawal
Description: Measurement of endothelial inflammation markers
Study: NCT00116584

Intervention type: DRUG
Group type: OTHER
Intervention: heliox
Description: continuous heliox therapy

Intervention type: DRUG
Group type: OTHER
Intervention: oxygen
Description: continuous oxygen therapy
Study: NCT03254992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASD - Abstract task
Description: Experimental group using Kinect with more virtual activity.
Study: NCT03435614

Intervention type: DRUG
Intervention: Opioids
Description: Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
Study: NCT03768505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib (ME-401)
Description: Zandelisib (ME-401) 60 mg
Study: NCT03254992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASD - Tangible task
Description: Experimental group using Keyboard with more real activity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TD - Abstract task
Description: Control group using Kinect with more virtual activity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TD - Tangible task
Description: Control group using Keyboard with more real activity.
Study: NCT00126555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
Study: NCT01073605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotonorm
Description: 1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotonorm
Description: 1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
Study: NCT02523183

Intervention type: DRUG
Intervention: Medical Cannabis
Description: Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
Study: NCT02748642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
Study: NCT03633123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D_PLEX
Description: D_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Description: Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure
Study: NCT04676269

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Amnion only
Description: Patients endometrium will be transplanted with amnion only (without seeded cells)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion - endometrium cells
Description: Patients endometrium will be transplanted with amnion seeded with endometrium cells isolated from the patients themselves
Study: NCT01424956

Intervention type: DEVICE
Intervention: Automated Breast Ultrasound (ABUS)
Description: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
Study: NCT02245776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Intrathecal autologous bone marrow mononuclear cell transplantation
Study: NCT00814658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
Study: NCT03070236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Select questions will be ask in the survey
Study: NCT04672551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR Treatment
Description: Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
Study: NCT00814658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Nimodipine 30 mg 3 times a day (tid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo three times a day (tid).
Study: NCT01449058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: taken orally
Study: NCT04676269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion - amnion epithelial cells
Description: Patients endometrium will be transplanted with amnion seeded with amnion epithelial stem cells isolated from other patients' caesarean sectio amnion membrane (tested HLA-DR negative to prevent rejection)
Study: NCT02565342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block
Study: NCT01380314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine + Imiquimod
Description: 150 mg x d during 28 days and cream applied every other day during 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Miltefosine 150 mg x day + Placebo
Description: 150 mg x d during 28 days and cream applied every other day during 3 weeks
Study: NCT02555709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as an oral capsule once daily
Study: NCT00715429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin d
Description: After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
Study: NCT02090101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAKINRA
Study: NCT02555709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as an oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as an oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as an oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as an oral capsule once daily
Study: NCT02605980

Intervention type: BEHAVIORAL
Intervention: Sedentary time

Intervention type: BEHAVIORAL
Intervention: Sedentary time
Study: NCT00492284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
Study: NCT00492284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg intravitreal injection
Study: NCT00492284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 0.5 mg intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 0.5 mg intravitreal injection
Study: NCT03624504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micra Transcatheter Pacing System (TPS)
Description: Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements
Study: NCT03936686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey tool to assess CVD risk factor knowledge
Description: The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey tool to assess CVD risk factor knowledge
Description: The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey tool to assess CVD risk factor knowledge
Description: The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey tool to assess CVD risk factor knowledge
Description: The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey tool to assess CVD risk factor knowledge
Description: The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.
Study: NCT04676269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion-EnSC-AESC
Description: Patients endometrium will be transplanted with amnion seeded with endometrium cells-amnion epithelial stem cells co-culture
Study: NCT02555709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as an oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as an oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as an oral capsule once daily
Study: NCT01069042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
Study: NCT03034447

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Children and parents are going to inform data regarding socioeconomical status, asthma and rhinitis diagnosis, asthma and rhinitis control, medications, sleep complaints, and sleep habits

Intervention type: OTHER
Group type: OTHER
Intervention: Lung Function Test
Description: Children are going to blow in a machine that measures how the lung is working

Intervention type: OTHER
Group type: OTHER
Intervention: Home Sleep Study
Description: Children are going to sleep at home with a device that tells if they stop breathing during sleep
Study: NCT02679417

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: 12 weeks of aerobic or resistant exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: 12 weeks of aerobic or resistant exercise
Study: NCT00454246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
Study: NCT00433589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anthracycline-based

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anthracycline-based

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline-based

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Study: NCT02208180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return of genomic results on cardiovascular disease risk
Description: Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Return of genomic results on cardiovascular disease risk
Description: Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
Study: NCT01303666

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular CSI
Description: After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TI of the knee
Description: This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles.
Study: NCT02246517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N2O
Study: NCT00433589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT02246517

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen